Bank of Cyprus Oncology Center, Nicosia, Cyprus.
Cancer Invest. 2022 Feb;40(2):124-131. doi: 10.1080/07357907.2021.1988962. Epub 2021 Oct 21.
Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC).
Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution's Data of patients diagnosed with L-LCNEC from April 2019 until December 2020 and evaluated their response to the combination of Platinum - Etoposide - Atezolizumab as first-line chemotherapy.
The overall observed response rate (ORR) of 75%. The median PFS was 6.85 months. The median response duration was 5.5 months.
Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.
肺大细胞神经内分泌癌（L-LCNEC）是一种越来越常见诊断的罕见神经内分泌肺癌类型。然而，对于晚期患者的最佳治疗方法尚不清楚。本文旨在介绍并比较我们将 L-LCNEC 作为小细胞肺癌（SCLC）进行治疗的经验。
共有 8 例 L-LCNEC 患者入组。我们通过访问机构的数据，回顾性地审查了 2019 年 4 月至 2020 年 12 月期间被诊断为 L-LCNEC 的患者的医疗记录和报告，并评估了他们对铂类药物-依托泊苷-阿特珠单抗联合治疗作为一线化疗的反应。
总体观察到的客观缓解率（ORR）为 75%。中位无进展生存期（PFS）为 6.85 个月。中位缓解持续时间为 5.5 个月。
将我们的发现与其他回顾性和前瞻性研究进行比较，似乎肺大细胞神经内分泌癌的系统治疗选择和管理应该是小细胞肺癌的治疗方法。
